US5072115A
(en)
*
|
1990-12-14 |
1991-12-10 |
Finnigan Corporation |
Interpretation of mass spectra of multiply charged ions of mixtures
|
US5157260A
(en)
*
|
1991-05-17 |
1992-10-20 |
Finnian Corporation |
Method and apparatus for focusing ions in viscous flow jet expansion region of an electrospray apparatus
|
US6436635B1
(en)
|
1992-11-06 |
2002-08-20 |
Boston University |
Solid phase sequencing of double-stranded nucleic acids
|
US5605798A
(en)
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
CA2153387A1
(fr)
*
|
1993-01-07 |
1994-07-21 |
Hubert Koester |
Sequencage de l'adn par spectrometrie de masse
|
US6194144B1
(en)
|
1993-01-07 |
2001-02-27 |
Sequenom, Inc. |
DNA sequencing by mass spectrometry
|
WO1994021822A1
(fr)
*
|
1993-03-19 |
1994-09-29 |
Sequenom, Inc. |
Sequençage de l'adn au moyen de la spectrometrie de masse par degradation a l'exonuclease
|
US5359196A
(en)
*
|
1993-05-24 |
1994-10-25 |
Hewlett-Packard Company |
Mass spectrometry with gas counterflow for particle beam
|
US5412208A
(en)
*
|
1994-01-13 |
1995-05-02 |
Mds Health Group Limited |
Ion spray with intersecting flow
|
US6146854A
(en)
*
|
1995-08-31 |
2000-11-14 |
Sequenom, Inc. |
Filtration processes, kits and devices for isolating plasmids
|
US5777324A
(en)
|
1996-09-19 |
1998-07-07 |
Sequenom, Inc. |
Method and apparatus for maldi analysis
|
US6207370B1
(en)
|
1997-09-02 |
2001-03-27 |
Sequenom, Inc. |
Diagnostics based on mass spectrometric detection of translated target polypeptides
|
US6294655B1
(en)
|
1998-04-03 |
2001-09-25 |
Hyseq, Inc. |
Anti-interleukin-1 receptor antagonist antibodies and uses thereof
|
US6541623B1
(en)
|
1998-04-03 |
2003-04-01 |
Hyseq, Inc. |
Interleukin—1 receptor antagonist and uses thereof
|
US6426191B1
(en)
|
1998-04-03 |
2002-07-30 |
Hyseq, Inc. |
Assays involving an IL-1 receptor antagonist
|
US6337072B1
(en)
|
1998-04-03 |
2002-01-08 |
Hyseq, Inc. |
Interleukin-1 receptor antagonist and recombinant production thereof
|
US6447771B1
(en)
|
1999-03-19 |
2002-09-10 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6476211B1
(en)
|
1998-07-16 |
2002-11-05 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
AU762392B2
(en)
|
1998-07-16 |
2003-06-26 |
Arca Biopharma, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6387645B1
(en)
|
1998-07-16 |
2002-05-14 |
Hyseq, Inc. |
Methods and materials relating to novel CD39-like polypeptides
|
US6780977B1
(en)
|
1999-01-29 |
2004-08-24 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6783959B1
(en)
|
1999-01-29 |
2004-08-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6350447B1
(en)
|
1999-01-29 |
2002-02-26 |
Hyseq, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6899875B1
(en)
|
1999-01-29 |
2005-05-31 |
Nuvelo, Inc. |
Methods and compositions relating to CD39-like polypeptides and nucleic acids
|
US6335013B1
(en)
|
1999-03-19 |
2002-01-01 |
Hyseq, Inc. |
Methods and materials relating to CD39-like polypeptides
|
US6890763B2
(en)
|
2001-04-30 |
2005-05-10 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
|
US7087435B2
(en)
|
2001-04-30 |
2006-08-08 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 2753 daltons
|
US6693080B2
(en)
|
2001-04-30 |
2004-02-17 |
Syn X Pharma |
Biopolymer marker indicative of disease state having a molecular weight of 1521 daltons
|
US7008800B2
(en)
|
2001-04-30 |
2006-03-07 |
Artemis Proteomics, Ltd. |
Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
|
US6617308B2
(en)
|
2001-04-30 |
2003-09-09 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
|
US6677303B2
(en)
|
2001-04-30 |
2004-01-13 |
Syn X Pharma |
Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
|
US6620787B2
(en)
|
2001-04-30 |
2003-09-16 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
|
US6620786B2
(en)
|
2001-04-30 |
2003-09-16 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having molecular weight of 2937 daltons
|
US6627608B2
(en)
|
2001-04-30 |
2003-09-30 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
|
US20020160533A1
(en)
|
2001-04-30 |
2002-10-31 |
George Jackowski |
Biopolymer marker indicative of disease state having a molecular of weight of 1525 daltons
|
US6756476B2
(en)
|
2001-04-30 |
2004-06-29 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 2021 daltons
|
US6599877B2
(en)
|
2001-04-30 |
2003-07-29 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
|
US7015004B2
(en)
|
2001-11-23 |
2006-03-21 |
Syn X Pharma, Inc. |
Inter-alpha trypsin inhibitor biopolymer marker indicative of insulin resistance
|
US7314717B2
(en)
|
2001-04-30 |
2008-01-01 |
Nanogen Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1562 daltons
|
US6627607B2
(en)
|
2001-04-30 |
2003-09-30 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
|
US6627606B2
(en)
|
2001-04-30 |
2003-09-30 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
|
US6602855B2
(en)
|
2001-04-30 |
2003-08-05 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
|
US20040198950A1
(en)
|
2001-04-30 |
2004-10-07 |
George Jackowski |
Biopolymer marker indicative of disease state having a molecular weight of 1518 daltons
|
US6703366B2
(en)
|
2001-04-30 |
2004-03-09 |
George Jackowski |
Biopolymer marker indicative of disease state having a molecular weight of 1,896 daltons
|
US6593298B2
(en)
|
2001-04-30 |
2003-07-15 |
Syn X Pharma, Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
|
US7294688B2
(en)
|
2001-04-30 |
2007-11-13 |
Nanogen Inc. |
Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
|
WO2002095002A2
(fr)
|
2001-05-22 |
2002-11-28 |
University Of Chicago |
Arn polymerase dependant de l'adn a brin unique de virion n4
|
US7179610B2
(en)
|
2001-11-23 |
2007-02-20 |
Nanogen Inc. |
Complement C3 precursor biopolymer markers indicative of insulin resistance
|
US7314762B2
(en)
|
2001-11-21 |
2008-01-01 |
Nanogen, Inc. |
Apolipoprotein biopolymer markers indicative of insulin resistance
|
US7132244B2
(en)
|
2001-11-21 |
2006-11-07 |
Syn X Pharma, Inc. |
Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
|
US7094549B2
(en)
|
2001-11-23 |
2006-08-22 |
Syn X Pharma, Inc. |
Fibronectin biopolymer marker indicative of insulin resistance
|
US7125678B2
(en)
|
2001-11-23 |
2006-10-24 |
Nanogen, Inc. |
Protein biopolymer markers predictive of type II diabetes
|
US7179606B2
(en)
|
2001-11-23 |
2007-02-20 |
Syn X Pharma, Inc. |
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
|
US6890722B2
(en)
|
2001-11-23 |
2005-05-10 |
Syn X Pharma, Inc. |
HP biopolymer markers predictive of insulin resistance
|
US7122327B2
(en)
|
2001-11-23 |
2006-10-17 |
Nanogen Inc. |
Biopolymer markers indicative of type II diabetes
|
US7135297B2
(en)
|
2001-11-23 |
2006-11-14 |
Nanogen Inc. |
Protein biopolymer markers indicative of insulin resistance
|
US7179605B2
(en)
|
2001-11-23 |
2007-02-20 |
Nanogen Inc. |
Fibronectin precursor biopolymer markers indicative of alzheimer's disease
|
US7052849B2
(en)
|
2001-11-23 |
2006-05-30 |
Syn X Pharma, Inc. |
Protein biopolymer markers predictive of insulin resistance
|
US7026129B2
(en)
|
2001-11-23 |
2006-04-11 |
Syn X Pharma, Inc. |
IG lambda biopolymer markers predictive of Alzheimers disease
|
US7097989B2
(en)
|
2001-11-23 |
2006-08-29 |
Syn X Pharma, Inc. |
Complement C3 precursor biopolymer markers predictive of type II diabetes
|
US7074576B2
(en)
|
2001-11-23 |
2006-07-11 |
Syn X Pharma, Inc. |
Protein biopolymer markers indicative of alzheimer's disease
|
WO2006102547A2
(fr)
|
2005-03-23 |
2006-09-28 |
Bio-Rad Laboratories, Inc. |
Procede destine a purifier des proteines
|
US20080317741A1
(en)
|
2005-11-16 |
2008-12-25 |
Anu Kinnunen |
Biomarkers For Anti-Nogo-A Antibody Treatment in Spinal Cord Injury
|
US8666681B2
(en)
*
|
2008-06-04 |
2014-03-04 |
Shimadzu Corporation |
Mass analysis data analyzing method and mass analysis data analyzing apparatus
|
JP6231219B2
(ja)
*
|
2013-12-24 |
2017-11-15 |
ウオーターズ・テクノロジーズ・コーポレイシヨン |
電気的に接地された電気スプレーための大気インターフェース
|
MX2018000729A
(es)
|
2015-07-17 |
2018-09-06 |
Harvard College |
Métodos para amplificar las secuencias de ácido nucleico.
|
RU2729116C2
(ru)
|
2015-12-16 |
2020-08-04 |
Гритстоун Онколоджи, Инк. |
Идентификация, производство и применение неоантигенов
|
GB2550591B
(en)
*
|
2016-05-24 |
2018-06-27 |
Microsaic Systems Plc |
A method for extracting mass information from low resolution mass-to-charge ratio spectra of multiply charged species
|
AU2018348165A1
(en)
|
2017-10-10 |
2020-05-21 |
Gritstone Bio, Inc. |
Neoantigen identification using hotspots
|
US11885815B2
(en)
|
2017-11-22 |
2024-01-30 |
Gritstone Bio, Inc. |
Reducing junction epitope presentation for neoantigens
|